Skip to main content

Advertisement

Table 2 Multivariable Cox proportional hazard model showing relative hazards (RH) for time-to-virologic-failure, fitted on the whole study population (n = 2,337)

From: A Prognostic Model for Estimating the Time to Virologic Failure in HIV-1 Infected Patients Undergoing a New Combination Antiretroviral Therapy Regimen

Factor RH 95% CI p-value
calendar year before 2004 vs. 2007 and after 2.06 (1.67-2.54) < 0.0001
  2004 vs. after 2007 and after 1.62 (1.29-2.03) < 0.0001
  2005-2006 vs. 2007 and after 1.28 (1.06-1.55) 0.0109
cART 2NRTI+1PI vs. 2NRTI+1NNRTI 1.03 (0.83-1.27) 0.8028
  2NRTI+1PI/r vs. 2NRTI+1NNRTI 0.63 (0.54-0.75) < 0.0001
  3NRTI vs. 2NRTI+1NNRTI 1.23 (0.92-1.64) 0.1599
age (per 10 years older) 0.89 (0.82-0.96) 0.0036
gender (male vs. female) 1.06 (0.91-1.23) 0.4668
mode of HIV-1 transmission male homosexual vs. heterosexual 1.08 (0.88-1.33) 0.4680
  IDU vs. heterosexual 1.08 (0.87-1.32) 0.4898
  other/unknown vs. heterosexual 1.08 (0.9-1.29) 0.4248
nationality non-Italian vs. Italian 1.23 (0.9-1.67) 0.1992
  unknown vs. Italian 0.94 (0.78-1.14) 0.5475
HCV/HBV coinfection unknown vs. no 1.18 (0.97-1.45) 0.1049
  yes vs. no 1.04 (0.82-1.32) 0.7277
HIV-1 RNA per log10 copies/ml higher 1.27 (1.17-1.39) < 0.0001
CD4+ count cells/mm3 < = 100 vs. > 500 1.57 (1.23-2) 0.0003
  > 100 and < = 199 vs. > 500 1.16 (0.93-1.45) 0.1968
  > 200 and < = 349 vs. > 500 1.22 (1-1.48) 0.0447
  > 350 and < = 499 vs. > 500 0.98 (0.79-1.21) 0.8202
interval time from the first HIV-1 positive test to ART initiation < = 12 vs. > 60 months 0.87 (0.67-1.13) 0.2944
  > 12 and < = 60 vs. > 60 months 1.01 (0.81-1.27) 0.9114
  unknown vs. > 60 months 0.92 (0.77-1.11) 0.3938
duration of prior ART exposures < = 6 vs. > 24 months 0.84 (0.7-1.01) 0.0626
  > 6 and < = 12 vs. > 24 months 0.92 (0.73-1.17) 0.5029
  > 12 and < = 24 vs. > 24 months 0.83 (0.66-1.03) 0.0890
previous AIDS-defining events (yes vs. no) 0.86 (0.7-1.05) 0.1379
#previous ART switches 1.03 (1-1.05) 0.0522
previous ART class exposure NRTI vs. ART-naïve 1.48 (1.01-2.17) 0.0441
  NRTI and NNRTI vs. ART-naïve 1.38 (0.99-1.93) 0.0546
  NRTI and NNRTI and PI vs. ART-naïve 1.43 (1.03-1.99) 0.0315
  NRTI and NNRTI and PI/r vs. ART-naïve 2.96 (2.16-4.06) < 0.0001
  NRTI and PI vs. ART-naïve 2.18 (1.64-2.89) < 0.0001
  NRTI and PI/r vs. ART-naïve 2.72 (1.98-3.75) < 0.0001
  other classes vs. ART-naïve 2.31 (1.31-4.05) 0.0036
previous exposure to suboptimal ART (yes vs. no) 0.85 (0.71-1.03) 0.0946
viral subtype 02_AG vs. B 0.98 (0.61-1.57) 0.9402
  C vs. B 1.41 (0.86-2.32) 0.1748
  F1 vs. B 0.57 (0.3-1.06) 0.0750
  other vs. B 1.26 (0.76-2.09) 0.3774
  undetermined vs. B 1.12 (0.88-1.42) 0.3527
GSS* ANRS per 1 point increase 0.72 (0.66-0.78) < 0.0001
  HIVdb per 1 point increase 0.68 (0.63-0.74) < 0.0001
  Rega per 1 point increase 0.71 (0.66-0.77) < 0.0001
  1. RH: relative hazard; CI: confidence interval; cART: combination antiretroviral therapy; NRTI: nucleoside/nucleotide reverse transcriptase inhibitors; NNRTI: non-nucloeside reverse transcriptase inhibitors; PI: protease inhibitors; PI/r: ritonavir-boosted PI; IDU: injecting drug users; HCV: hepatitis C virus; HBV: hepatitis B virus; ART: antiretroviral therapy; GSS: genotypic susceptibility score; *fitted separately one from each other.